A retrospective study of the clinical and laboratory predictors and morphological characteristics of the parathyroid carcinoma

Cover Page
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


Background: there are no specific markers of the parathyroid carcinoma (PC) therefore, the development of algorithms for identifying high-risk patients is an urgent task.

Aims: to determine the clinical and laboratory predictors of PC and to identify the factors of a poor prognosis.

Materials and methods: A multicenter retrospective study included 242 patients with primary hyperparathyroidism (PHPT) who were divided into groups: 162 with adenomas, 30 with аtypical adenomas (АА) and 50 patients with PC. Data collection and analysis was carried out from 2017 to 2020. The primary goal— assessment of the possibility of PС using preoperative laboratory and instrumental data. The group of PC was divided into subgroups: the patients in recurrences (n=17) and remission (n=33). The level of the total calcium, albumin, alkaline phosphatase (ALP), ionized calcium (Ca ++) in the blood were determined on the automatic biochemical analyzer; the level of parathyroid hormone (PTH) by electrochemoluminescent analyzer. The size of the PG determined by the ellipse formula: V (cm3) = (A × B × C) × 0.49. Statistical analysis was performed with Statistica 13 and SPSS software packages. For multiple comparisons, the Bonferroni correction was applied.

Results: the group of patients with increased risk of PC include persons with increased level of PTH >443 pg/ml, Ca++ >1.5 mmol/l, total calcium >3.2 mmol/l, ALP >176 IU/L, V of tumors >2.6 cm3, largest size >22.5 mm (p <0,001). Heterogeneous structure is more typical to PC compared to the АА (p = 0,004 and р = 0,011), the same applies to indefinite contour (р = 0,001 и р = 0,011). Pathological mitosis is a prognostically unfavorable factor of recurrence of PC (р=0,007).

Conclusions: the patients with PC and AA are characterized with more aggressive course of PHPT compared to the group of adenomas.

Full Text

Restricted Access

About the authors

Julia A. Krupinova

Endocrinology Research Centre

Author for correspondence.
Email: j.krupinova@gmail.com
ORCID iD: 0000-0001-7963-5022
SPIN-code: 6279-8247

Russian Federation, Moscow

MD, research associate

Iya A. Voronkova

Endocrinology Research Centre; Moscow Regional Research and Clinical Institute

Email: iya-v@yandex.ru
ORCID iD: 0000-0001-6687-3240
SPIN-code: 9685-1371

Russian Federation, Moscow; Moscow


Alina R. Ajnetdinova

Endocrinology Research Centre

Email: 9803005@mail.com
ORCID iD: 0000-0001-6935-3187
SPIN-code: 9617-7460

Russian Federation, Moscow


Aleksandr Y. Abrosimov

Endocrinology Research Centre

Email: nikitarusskikh@mail.ru
ORCID iD: 0000-0001-8284-9996
SPIN-code: 4089-9502

Russian Federation, Moscow

MD, PhD, Professor

Irina V. Kryukova

Moscow Regional Research and Clinical Institute

Email: kiv200877@yandex.ru
ORCID iD: 0000-0002-7876-5105
SPIN-code: 7669-3010

Russian Federation, Moscow

MD, PhD, Assistant Professor

Stanislav V. Lukyanov

Rostov State Medical University

Email: svluk@rambler.ru
ORCID iD: 0000-0002-3317-0108
SPIN-code: 4181-8431

Russian Federation, Rostov-on-Don

MD, PhD, Assistant Professor

Julia S. Veretennikova

Endocrinology Research Centre

Email: veretennikova-j@mail.ru
ORCID iD: 0000-0001-8849-9595
SPIN-code: 7410-9041

Russian Federation, Moscow

Clinical Resident

Larisa K. Tevosyan

Moscow Regional Research and Clinical Institute

Email: tlh_moscou@mail.ru
ORCID iD: 0000-0002-8954-1633
SPIN-code: 7376-4180

Russian Federation, Moscow


Galina A. Melnichenko

Endocrinology Research Centre

Email: teofrast2000@mail.ru
ORCID iD: 0000-0002-5634-7877
SPIN-code: 8615-0038

Russian Federation, Moscow

MD, PhD, Professor, Academician of the RAS

Natalia G. Mokrysheva

Endocrinology Research Centre

Email: parathyroid.enc@gmail.com
ORCID iD: 0000-0002-9717-9742
SPIN-code: 5624-3875

Russian Federation, Moscow

MD, PhD, Professor, Corresponding Member of the RAS


  1. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985–1995: A national cancer data base report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1999;86(3):538–544. doi: https://doi.org/10.1002/(sici)1097-0142(19990801)86:3<538::aid-cncr25>3.0.co;2-k
  2. Lee PK, Jarosek SL, Virnig BA, et al. Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer. 2007;109(9):1736–1741. doi: https://doi.org/10.1002/cncr.22599
  3. Talat N, Schulte K-M. Clinical Presentation, Staging and Long-Term Evolution of Parathyroid Cancer. Ann Surg Oncol. 2010;17(8):2156–2174. doi: https://doi.org/10.1245/s10434-010-1003-6
  4. Sadler C, Gow KW, Beierle EA, et al. Parathyroid carcinoma in more than 1,000 patients: A population-level analysis. Surgery. 2014;156(6):1622–1629. doi: https://doi.org/10.1016/j.surg.2014.08.069
  5. Villar-del-Moral J, Jiménez-García A, Salvador-Egea P, et al. Prognostic factors and staging systems in parathyroid cancer: a multicenter cohort study. Surgery. 2014;156(5):1132–1144. doi: https://doi.org/10.1016/j.surg.2014.05.014
  6. Xue S, Chen H, Lv C, et al. Preoperative diagnosis and prognosis in 40 Parathyroid Carcinoma Patients. Clin Endocrinol (Oxf). 2016;85(1):29–36. doi: https://doi.org/10.1111/cen.13055
  7. van der Zwan JM, Mallone S, van Dijk B, et al. Carcinoma of endocrine organs: results of the RARECARE project. Eur J Cancer. 2012;48(13):1923–1931. doi: https://doi.org/10.1016/j.ejca.2012.01.029
  8. James BC, Aschebrook-Kilfoy B, Cipriani N, et al. The incidence and survival of rare cancers of the thyroid, parathyroid, adrenal, and pancreas. Ann Surg Oncol. 2016;23(2):424–433. doi: https://doi.org/10.1245/s10434-015-4901-9
  9. Asare EA, Sturgeon C, Winchester DJ, et al. Parathyroid carcinoma: An update on treatment outcomes and prognostic factors from the National Cancer Data Base (NCDB). Ann Surg Oncol. 2015;22(12):3990–3995. doi: https://doi.org/10.1245/s10434-015-4672-3
  10. Schulte KM, Talat N, Galata G, et al. Oncologic resection achieving r0 margins improves disease-free survival in parathyroid cancer. Ann Surg Oncol. 2014;21(6):1891–1897. doi: https://doi.org/10.1245/s10434-014-3530-z
  11. Hsu K-T, Sippel RS, Chen H, Schneider DF, et al. Is central lymph node dissection necessary for parathyroid carcinoma? Surgery. 2014;156(6:)1336–1341; discussion 1341. doi: https://doi.org/10.1016/j.surg.2014.08.005
  12. Silva-Figueroa AM, Hess KR, Williams MD, et al. Prognostic scoring system to risk stratify parathyroid carcinoma. J Am Coll Surg. 2017;5;S1072-7515(17)30179-5. doi: https://doi.org/10.1016/j.jamcollsurg.2017.01.060
  13. Brown S, O’Neill C, Suliburk J, et al. Parathyroid carcinoma: Increasing incidence and changing presentation. ANZ J Surg. 2011;81(7–8):528–532. doi: https://doi.org/10.1111/j.1445-2197.2010.05594.x
  14. Kebebew E. Parathyroid carcinoma. Curr Treat Options Oncol. 2001;2(4):347–354. doi: https://doi.org/10.1007/s11864-001-0028-2
  15. Lo WM, Good ML, Nilubol N, et al. Tumor size and presence of metastatic disease at diagnosis are associated with disease-specific survival in parathyroid carcinoma. Ann Surg Oncol. 2018;25(9):2535–2540. doi: https://doi.org/10.1245/s10434-018-6559-6
  16. Shane E. Clinical review 122: Parathyroid carcinoma. J Clin Endocrinol Metab. 2001;86(2):485–493. doi: https://doi.org/10.1210/jcem.86.2.7207
  17. DeLellis RA, Arnold A, Bilezikian JP WHO classification of tumours of endocrine organs. Parathyroid carcinoma. Lloyd RV, Osamura RY, Kloppel G, Rosai J. (eds). 2017. P. 147–158.
  18. Cetani F, Marcocci C, Torregrossa L, Pardi E. Atypical parathyroid adenomas: challenging lesions in the differential diagnosis of endocrine tumors. Endocr Relat Cancer. 2019;26(7):R441–R464. doi: https://doi.org/10.1530/ERC-19-0135
  19. Landry C, Wang T, Asare E. Parathyroid. AJCC Cancer Staging Manual. Springer; 2017. P. 903–910.
  20. Мокрышева Н.Г., Крупинова Ю.А., Мирная С.С. Клинические и лабораторно-инструментальные возможности предоперационной диагностики рака околощитовидных желез // Эндокринная хирургия. — 2017. — Т. 11. — № 3. — С. 136–145. [Mokrysheva NG, Krupinova JA, Mirnaya SS. Clinical, laboratory and instrumental methods of pre-surgical diagnosis of the parathyroid glands cancer. Endocrine Surgery. 2017;11(3):136–145. (In Russ.)] doi: https://doi.org/10.14341/serg20173136-145
  21. Rodrigo JP, Hernandez-Prera JC, Randolph GW, et al. Parathyroid cancer: An update. Cancer Treat Rev. 2020;86:102012. doi: https://doi.org/10.1016/j.ctrv.2020.102012
  22. Ryhänen EM, Leijon H, Metso S, et al. A nationwide study on parathyroid carcinoma. Acta Oncol. 2017;56(7):991–1003. doi: https://doi.org/10.1080/0284186X.2017.1306103
  23. Schulte K-M, Talat N. Diagnosis and management of parathyroid cancer. Nat Rev Endocrinol. 2012;8(10):612–622. doi: https://doi.org/10.1038/nrendo.2012.102
  24. Erovic BM, Goldstein DP, Kim D, et al. Parathyroid cancer: outcome analysis of 16 patients treated at the Princess Margaret Hospital. Head Neck. 2013;35(1):35–39. doi: https://doi.org/10.1002/hed.22908
  25. Busaidy NL, Jimenez C, Habra MA, et al. Parathyroid carcinoma: a 22-year experience. Head Neck. 2004;26(8):716–726. doi: https://doi.org/10.1002/hed.20049
  26. Liu R, Xia Y, Chen C, et al. Ultrasound combined with biochemical parameters can predict parathyroid carcinoma in patients with primary hyperparathyroidism. Endocrine. 2019;66(3):673–681 doi: https://doi.org/10.1007/s12020-019-02069-7
  27. Wang L, Han D, Chen W, et al. Non-functional parathyroid carcinoma: A case report and review of the literature. Cancer Biol Ther. 2015;16(11):1569–1576.
  28. Smith RB, Evasovich M, Girod DA, et al. Ultrasound for localization in primary hyperparathyroidism. Otolaryngol Head Neck Surg. 2013;149(3):366–371. doi: https://doi.org/10.1177/0194599813491063
  29. Nam M, Jeong H-S, Shin JH. Differentiation of parathyroid carcinoma and adenoma by preoperative ultrasonography. Acta Radiol. 2017;58(6):670–675. doi: https://doi.org/10.1177/0284185116666418
  30. Hara H, Igarashi A, Yano Y, et al. Ultrasonographic features of parathyroid carcinoma. Endocr J. 2001;48(2):213–217. doi: https://doi.org/10.1507/endocrj.48.213
  31. Bondenson L, et al. Parathyroid carcinoma. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds). Pathology and Genetics. Tumors of Endocrine Organs. WHO Classification of Tumours. Lyon: IARC Press; 2004. P. 124–127.
  32. DeLellis RA, et al. Parathyroid adenoma. In: Lloyd RV, Osamura RY, Kloppel G, Rosai J (eds). WHO classification of tumours of endocrine organs. Lyon: IARC; 2017. P. 153–158.
  33. Fernandez-Ranvier GG, Khanafshar E, Jensen K, et al. Parathyroid carcinoma, atypical parathyroid adenoma, or parathyromatosis? Cancer. 2007;110(2):255–264. doi: https://doi.org/10.1002/cncr.22790
  34. DeLellis RA. Parathyroid tumors and related disorders. Mod Pathol. 2011;24 Suppl 2:S78-93. doi: https://doi.org/10.1038/modpathol.2010.132
  35. Duan K, Mete Ö. Parathyroid Carcinoma: Diagnosis and Clinical Implications. Turk Patoloji Derg. 2015;31(Suppl1):80–97. doi: https://doi.org/10.5146/tjpath.2015.01316
  36. Katz L, Khalek MA, Crawford B, Kandil E. Robotic-assisted transaxillary parathyroidectomy of an atypical adenoma. Minim Invasive Ther Allied Technol. 2012;21(3):201–205. doi: https://doi.org/10.3109/13645706.2011.581291
  37. Silva-Figueroa A, Villalobos P, Williams MD, et al. Characterizing parathyroid carcinomas and atypical neoplasms based on the expression of programmed death-ligand 1 expression and the presence of tumor-infiltrating lymphocytes and macrophages. Surgery. 2018;164(5):960–964. doi: https://doi.org/10.1016/j.surg.2018.06.013
  38. Kar A, Kar T, Dha I, Panda S. Squash cytodiagnosis of synchronous papillary serous carcinoma of ovary and endometrium with demonstration of serous tubal intraepithelial carcinoma as a precursor lesion. Indian J Pathol Microbiol. 2017; 60(1):125-127 doi: https://doi.org/10.4103/0377-4929.200039
  39. Harari A, Waring A, Fernandez-Ranvier G, et al. Parathyroid carcinoma: a 43-year outcome and survival analysis. J Clin Endocrinol Metab. 2011;96(12):3679–3686 doi: https://doi.org/10.1210/jc.2011-1571
  40. Kebebew E, Arici C, Duk QY, Clark OH. Localization and reoperation results for persistent and recurrent parathyroid carcinoma. Arch Surg. 2001;136(8):878–885. doi: https://doi.org/10.1001/archsurg.136.8.878
  41. Asare EA, Sturgeon C, Winchester DJ, et al. Parathyroid Carcinoma: An Update on Treatment Outcomes and Prognostic Factors from the National Cancer Data Base (NCDB). Ann Surg Oncol. 2015;22(12):3990–3995. doi: https://doi.org/10.1245/s10434-015-4672-3
  42. Salcuni AS, Cetani F, Guarnieri V, et al. Parathyroid carcinoma. Best Pract Res Clin Endocrinol Metab. 2018;32(6):877–889. doi: https://doi.org/10.1,016/j.beem.2018.11.002
  43. Schulte K-M, Gill AJ, Barczynski M, et al. Classification of parathyroid cancer. Ann Surg Oncol. 2012;19(8):2620–2628. doi: https://doi.org/10.1245/s10434-012-2306-6
  44. Williams MD, DeLellis RA, Erickson LA, et al. Pathology Data Set for Reporting Parathyroid Carcinoma & Atypical Parathyroid Neoplasm: Recommendations from the International Collaboration on Cancer Reporting. Hum Pathol. 2020;S0046-8177(20)30131-3. doi: https://doi.org/10.1016/j.humpath.2020.07.008.

Supplementary files

Supplementary Files Action
Figure 4. Vascular invasion of the capsule and surrounding soft tissue

Download (199KB) Indexing metadata
Figure 1. Parathyroid carcinomas from the Chief cells with different degrees of cytonuclear atypia

Download (3MB) Indexing metadata
Fig. 1. Study design

Download (463KB) Indexing metadata
Fig. 2. ROC-analysis of laboratory and instrumental predictors of differential diagnosis of PTG masses: A - ROC- iPTG analysis, AUC = 0.884 (95% CI 0.821–0.948); B - ROC analysis of Ca ++, AUC = 0.840 (95% CI 0.756–0.924); B - ROC analysis corrected calcium, AUC = 0.835 (95% CI 0.759-0.910); D - ROC analysis of alkaline phosphatase, AUC = 0.835 (95% CI 0.759-0.910); D - ROC analysis of the largest size of education by ultrasound, AUC = 0.832 (95% CI 0.766–0.899); E - ROC analysis volume of education by ultrasound, AUC = 0.877 (95% CI 0.812-0.941)

Download (302KB) Indexing metadata
Fig. 3. Cancer of the thyroid gland: A - wide fibrous cords; B - invasion of the tumor capsule; B - increased mitotic activity of PTG carcinoma (3 mitoses in 1 RPZ); D - germination of PTG cancer (1) into the tissue of the thyroid gland (2)

Download (1MB) Indexing metadata



Abstract - 298

PDF (Russian) - 3


Article Metrics

Metrics Loading ...



Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies